Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 543-549

  Keiser, Jennifer ^a   Gruyer, Marie Stella ^b   Perrottet, Nancy ^c   Zanolari, Boris ^c   Mercier, Thomas ^c   Decosterd, Laurent ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Artemisinins; Food borne trematodiasis; LC MS MS

Indexed keywords

ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FASCIOLA HEPATICA; FASCIOLIASIS; FEMALE; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTHELMINTICS; AREA UNDER CURVE; ARTEMISININS; CHROMATOGRAPHY, LIQUID; FASCIOLA HEPATICA; FASCIOLIASIS; FEMALE; MASS SPECTROMETRY; PLASMA; RATS;

EID: 60649099384     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn550     Document Type: Article

References (27)

1. Keiser J, Utzinger J. Food-borne trematodiasis: Current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 2007; 23: 555-62.
2. Mas-Coma S. Human fascioliasis: Epidemiological patterns in human endemic areas of South America, Africa and Asia. Southeast Asian J Trop Med Public Health 2004; 35: 1-11.
3. Keiser J, Engels D, Büscher G et al. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Invest Drugs 2005; 14: 1513-26.
4. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77: 181-92.
5. Utzinger J, Xiao SH, Tanner M et al. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007; 8 105-16.
6. Keiser J, Xiao SH, Tanner M et al. Artesunate and artemether are effective fasciolicides in the rat model and in vitro. J Antimicrob Chemother 2006; 57: 1139-45.
7. Keiser J, Rinaldi L, Veneziano V et al. Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep. Parasitol Res 2008; 103: 517-22.
8. Hien TT, Truong NT, Minh NH et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008; 78: 388-92.
9. Maffei Facino R, Carini M. Loss of substrate binding capacity of the hepatic microsomal cytochrome P-450 in Fasciola hepatica infected rats: Toxicological implications. Farmaco [Sci] 1982; 37: 184-91.
10. Behm CA, Sangster NC. Pathology, pathophysiology and clinical aspects. In: Dalton JP, ed. Fasciolosis. London: CAB International, 1999; 185-224.
11. Shah VP, Midha KK, Findlay JW et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7.
12. Galtier P, Cambon-Gros C, Fernandez Y et al. Fasciola hepatica: liver microsomal membrane functions in host rat. Exp Parasitol 1994; 78: 175-82.
13. Keiser J, Utzinger J, Tanner M et al. The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J Antimicrob Chemother 2006; 58: 1193-7.
14. Li Q, Xie LH, Johnson TO et al. Toxicity evaluation of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Trans R Soc Trop Med Hyg 2007; 101: 104-12.
15. Batty KT, Le AT, Ilett KF et al. A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Am J Trop Med Hyg 1998; 59: 823-7.
16. Batty KT, Ilett KF, Powell SM et al. Relative bioavailability of artesunate and dihydroartemisinin: Investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Am J Trop Med Hyg 2002; 66: 130-6.
17. Li QG, Peggins JO, Fleckenstein LL et al. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J Pharm Pharmacol 1998; 50: 173-82.
18. Olliaro PL, Nair NK, Sathasivam K et al. Pharmacokinetics of artesunate after single oral administration to rats. BMC Pharmacol 2001; 1: 12.
19. Newton P, Suputtamongkol Y, Teja-Isavadharm P et al. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 972-7.
20. 14C] artesunate in rat tissues by quantitative whole-body autoradiography and tissue dissection techniques. J Pharm Biomed Anal 2008; 48: 876-84.
21. Vennerstrom JL, Arbe-Barnes S, Brun R et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430: 900-4.
22. Batty KT, Davis TM, Thu LT et al. Selective high-performance liquid chromatographic determination of artesunate and α- and β-dihydroartemisinin in patients with falciparum malaria. J Chromatogr B Biomed Appl 1996; 677: 345-50.
23. Na-Bangchang K, Congpuong K, Hung LN et al. Simple high-performance liquid chromatographic method with electrochemical detection for the simultaneous determination of artesunate and dihydroartemisinin in biological fluids. J Chromatogr B Biomed Appl 1998; 708: 201-7.
24. Naik H, Murry DJ, Kirsch LE et al. Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 233-42.
25. Messori L, Gabbiani C, Casini A et al. The reaction of artemisinins with hemoglobin: A unified picture. Bioorg Med Chem 2006; 14: 2972-7.
26. French CL, Yaun SS, Baldwin LA et al. Potency ranking of methemoglobin-forming agents. J Appl Toxicol 1995; 15: 167-74.
27. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008; 358: 1829-36.